Icon

Zoryve - (0.3% ; Cream)

Roflumilast Arcutis
0.3% ; Cream
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
None None
ZORYVE is a phosphodiesterase 4 inhibitor indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older.
Yes
Zoryve Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6
******* **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, **** **** ** *** **, ****
********** ** ******* ****** ** *********** ******* *********** *********** ****** ******** ******** *** ****** **** **** ********** ** ******* ****** ** *********** ******* *********** *********** ****** ******** ******** *** ****** ****-**** ********** ** ******* ****** ** *********** ********** ** ******* ****** ** ***********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******* *** \ ********* *** **, **** ******* **** *** ****** *** ****
  1. *** **, **** : * **** ** ** ***** *** ***** ** *** ***.
  2. *** **, **** : ******* ******** ******* ***** *** **** ** ******.
  3. *** **, **** : ******* **** ******* **** ************ ** ****** ** '***, '***, '***, '***, '*** *** '*** ** ** ** ********.
  4. *** **, **** : ******* ***** ******* **** ******* ******* **** ************ ** ****** ** '***, '***, '***, '***, '*** *** '*** ** ** ** *** *****.
  5. *** **, **** : ******* *** *********** ********* *** **** ***** ** ****. ******** **** ** *** *******.

Zoryve - ()

Roflumilast None
Less Than $1000 mn
None None
None None
None None
ZORYVE foam, 0.3%, is a phosphodiesterase 4 inhibitor indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.
Yes
Zoryve Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16 Patent 17 Patent 18 Patent 19 Patent 20
*** *********
********** ** ******* ****** ** *********** ********** ** ******* ****** ** *********** ********** ** ******* ****** ** *********** ******* *********** *********** ****** ******** ******** *** ****** **** **** ******* *********** *********** ****** ********** ********** ********** ** ******* ****** ** *********** ******* *********** *********** ****** ******** ******** *** ****** ****-**** ****** *** ******** **** ******* **** ************** ** *****************-* ********** ******* *********** *********** ****** ******** ******** *** ****** **** **** ******* *********** *********** ****** ******** ******** *** ****** ****-**** *********** ************ **** ** ******** *************** ******* *********** ************ **** ** ******** *************** ******* ****** *** ******** **** ******* **** ************** ** *****************-* ********** *********** ************ **** ** ******** *************** ******* ********** ** ******* ****** ** *********** ******* *********** *********** ****** ******** ******** *** ****** ****-**** ******* *********** *********** ****** ********** ********** ********** ** ******* ****** ** *********** ****** *** ******** **** ******* **** ************** ** *****************-* ********** ******* *********** ******* *****

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.